课题基金 / 基金详情

Elucidating the therapeutic potential of targeting aryl hydrocarbon receptors in macrophages in pancreatic ductal adenocarcinoma to improve immunotherapy

Elucidating the therapeutic potential of targeting aryl hydrocarbon receptors in macrophages in pancreatic ductal adenocarcinoma to improve immunotherapy
阐明针对胰腺导管腺癌巨噬细胞中芳基烃受体改善免疫治疗的治疗潜力
批准号：
428966
负责人：
Liu Zhe Qi
金额：
$1.27万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-12-01 至 2020-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=428966&lang=en
关键词：
Cancer Immunotherapy Cyototoxic T Lymphocytes Immunosuppression Immunotolerance Macrophages Pancreatic Ductal Adenocarcinoma Therapeutic Validation Tumour Microenvironment

项目摘要

项目成果

Liu Zhe Qi的其他基金

相关文献

中文摘要
翻译
胰腺导管腺癌（PDAC）是胰腺的一种恶性癌症，在所有主要癌症类型中，5年患者生存率最低。癌症免疫疗法是治疗癌症患者的一种越来越受欢迎和有前途的方法。我
英文摘要
"Pancreatic ductal adenocarcinoma (PDAC) is a malignant cancer of the pancreas and has the lowest 5-year patient survival rate of all major cancer types. Cancer immunotherapy is an increasingly popular and promising approach to treating cancer patients. I
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating the effects of the microbiome and the aryl hydrocarbon receptor on CD8+ T cell function in pancreatic ductal adenocarcinoma